Form 8-K Principal Accountant
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
________________
FORM
8-K
________________
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
report (Date of earliest event reported): January
1, 2007
ATHEROGENICS,
INC.
(Exact
Name of Registrant as Specified in its Charter)
|
Georgia
|
0-31261
|
58-2108232
|
|
(State
or other jurisdiction
|
(Commission
|
(I.R.S.
Employer
|
|
of
incorporation)
|
File
Number)
|
Identification
Number)
|
8995
Westside Parkway
Alpharetta,
GA 30004
(Address
of principal executive offices)
Registrant's
telephone number, including area code (678)
336-2500
_________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers; Compensatory Arrangements of Certain
Officers.
Effective
January 1, 2007, Charles A. Deignan, became Vice President of Finance and
Administration and Principal Accounting Officer of AtheroGenics, Inc. He had
previously served as Senior Director of Finance and Administration since
January 2002 and as Director of Finance and Administration from August 1999
to December 2001. Mr. Deignan has been the Assistant Secretary of AtheroGenics
since 1999. From 1994 until joining AtheroGenics, Mr. Deignan held several
management positions at AAIPharma Inc., a pharmaceutical development company,
most recently as Division Controller. From 1988 until 1993 Mr. Deignan held
a
number of positions at Schering-Plough Corporation, most recently as Finance
Manager. Mr. Deignan received a B.S. in Business Administration from Boston
University and is a Certified Managerial Accountant. Mr. Deignan will continue
to report to Mark P. Colonnese, Executive Vice President, Commercial Operations
and Chief Financial Officer.
During
the last fiscal year there have been no related party transactions between
Mr.
Deignan and AtheroGenics. Mr. Deignan has no family relationship between any
director, executive officer, or person nominated or chosen by AtheroGenics
to
become a director or executive officer.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
| |
|
ATHEROGENICS,
INC.
|
| |
|
|
|
Date:
January 4, 2007
|
|
/s/MARK
P. COLONNESE
|
| |
|
Name:
Mark P. Colonnese
|
| |
|
Title:
Executive Vice President, Commercial Operations
|
| |
|
and
Chief Financial Officer
|